Liven Pharma Limited (PSX:LIVEN)
Pakistan · Delayed Price · Currency is PKR 31.48
-0.42 (-1.32%)
At close: Oct 19, 2026
Liven Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 105.81 | 127.27 | 245.09 | - | - | |
Revenue Growth | -16.87% | -48.07% | - | - | - |
Cost of Revenue | 116.53 | 111.45 | 182.96 | - | - |
Gross Profit | -10.73 | 15.82 | 62.14 | - | - |
Selling, General & Admin | 46.86 | 389.03 | 19.14 | 2.12 | 2.95 |
Other Operating Expenses | 18.34 | 88.84 | 1.23 | - | - |
Operating Expenses | 65.2 | 507.53 | 20.37 | 15.22 | 17.51 |
Operating Income | -75.93 | -491.71 | 41.77 | -15.22 | -17.51 |
Interest Expense | -2.45 | -0.73 | -0.02 | - | - |
Interest & Investment Income | 1.36 | 0.31 | - | - | - |
Currency Exchange Gain (Loss) | -0.07 | - | - | - | - |
Other Non Operating Income (Expenses) | 6.11 | -0.06 | -0 | -0 | -0 |
EBT Excluding Unusual Items | -70.99 | -492.19 | 41.74 | -15.23 | -17.51 |
Gain (Loss) on Sale of Assets | 4.67 | - | - | - | - |
Pretax Income | -66.32 | -492.19 | 41.74 | -15.23 | -17.51 |
Income Tax Expense | -35.18 | 92.27 | - | -2.9 | -3.22 |
Net Income | -31.14 | -584.46 | 41.74 | -12.33 | -14.29 |
Net Income to Common | -31.14 | -584.46 | 41.74 | -12.33 | -14.29 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 112 | 82 | 0 | 12 | 12 |
Shares Outstanding (Diluted) | 112 | 82 | 0 | 12 | 12 |
Shares Change | 35.87% | 205288.50% | -99.67% | - | - |
EPS (Basic) | -0.28 | -7.11 | 1043.60 | -1.02 | -1.18 |
EPS (Diluted) | -0.28 | -7.11 | 1043.60 | -1.02 | -1.18 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -20.68 | -24.56 | 13.8 | -2.27 | -2.26 |
Free Cash Flow Per Share | -0.18 | -0.30 | 345.08 | -0.19 | -0.19 |
Gross Margin | -10.14% | 12.43% | 25.35% | - | - |
Operating Margin | -71.76% | -386.34% | 17.04% | - | - |
Profit Margin | -29.43% | -459.22% | 17.03% | - | - |
Free Cash Flow Margin | -19.54% | -19.30% | 5.63% | - | - |
EBITDA | -46.51 | -465.93 | 64.93 | -2.12 | -2.95 |
EBITDA Margin | -43.96% | - | 26.49% | - | - |
D&A For EBITDA | 29.42 | 25.78 | 23.16 | 13.1 | 14.56 |
EBIT | -75.93 | -491.71 | 41.77 | -15.22 | -17.51 |
EBIT Margin | -71.76% | - | 17.04% | - | - |
Advertising Expenses | 1.03 | 3.26 | 0.12 | - | - |